274 related articles for article (PubMed ID: 23817177)
21. Novel therapeutic strategies for MLL-rearranged leukemias.
Wong NM; So CWE
Biochim Biophys Acta Gene Regul Mech; 2020 Sep; 1863(9):194584. PubMed ID: 32534041
[TBL] [Abstract][Full Text] [Related]
22. Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1.
Li X; Vradii D; Gutierrez S; Lian JB; van Wijnen AJ; Stein JL; Stein GS; Javed A
J Cell Biochem; 2005 Nov; 96(4):795-809. PubMed ID: 16149049
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
24. RUNX1: A microRNA hub in normal and malignant hematopoiesis.
Rossetti S; Sacchi N
Int J Mol Sci; 2013 Jan; 14(1):1566-88. PubMed ID: 23344057
[TBL] [Abstract][Full Text] [Related]
25. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation.
Balbach ST; Orkin SH
Cancer Discov; 2016 Jul; 6(7):700-2. PubMed ID: 27371576
[TBL] [Abstract][Full Text] [Related]
26. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
Osato M
Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
[TBL] [Abstract][Full Text] [Related]
27. Role of RUNX1 in hematological malignancies.
Sood R; Kamikubo Y; Liu P
Blood; 2017 Apr; 129(15):2070-2082. PubMed ID: 28179279
[TBL] [Abstract][Full Text] [Related]
28. Gatekeeper function of the RUNX1 transcription factor in acute leukemia.
Niebuhr B; Fischer M; Täger M; Cammenga J; Stocking C
Blood Cells Mol Dis; 2008; 40(2):211-8. PubMed ID: 17920312
[TBL] [Abstract][Full Text] [Related]
29. Gene rearrangements of MLL and RUNX1 sporadically occur in normal CD34
Harada Y; Shingai N; Ding Y; Sadato D; Hayashi Y; Yamaguchi M; Okuyama Y; Shimoyama T; Ohashi K; Harada H
Cancer Sci; 2020 May; 111(5):1851-1855. PubMed ID: 32216001
[TBL] [Abstract][Full Text] [Related]
30. The Leukemia Inhibitory Factor Receptor Gene Is a Direct Target of RUNX1.
Qadi AA; Taberlay PC; Phillips JL; Young A; West AC; Brettingham-Moore KH; Dickinson JL; Holloway AF
J Cell Biochem; 2016 Jan; 117(1):49-58. PubMed ID: 26060100
[TBL] [Abstract][Full Text] [Related]
31. In focus: MLL-rearranged leukemia.
de Boer J; Walf-Vorderwülbecke V; Williams O
Leukemia; 2013 Jun; 27(6):1224-8. PubMed ID: 23515098
[TBL] [Abstract][Full Text] [Related]
32. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.
Cammenga J; Niebuhr B; Horn S; Bergholz U; Putz G; Buchholz F; Löhler J; Stocking C
Cancer Res; 2007 Jan; 67(2):537-45. PubMed ID: 17234761
[TBL] [Abstract][Full Text] [Related]
33. Genotoxicity of etoposide: greater susceptibility of MLL than other target genes.
Ng A; Taylor GM; Eden OB
Cancer Genet Cytogenet; 2006 Jan; 164(2):164-7. PubMed ID: 16434323
[TBL] [Abstract][Full Text] [Related]
34. EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.
Charmsaz S; Beckett K; Smith FM; Bruedigam C; Moore AS; Al-Ejeh F; Lane SW; Boyd AW
PLoS One; 2015; 10(6):e0130692. PubMed ID: 26083390
[TBL] [Abstract][Full Text] [Related]
35. Runx1/AML1 in normal and abnormal hematopoiesis.
Yamagata T; Maki K; Mitani K
Int J Hematol; 2005 Jul; 82(1):1-8. PubMed ID: 16105753
[TBL] [Abstract][Full Text] [Related]
36. The genome-wide molecular signature of transcription factors in leukemia.
Prange KH; Singh AA; Martens JH
Exp Hematol; 2014 Aug; 42(8):637-50. PubMed ID: 24814246
[TBL] [Abstract][Full Text] [Related]
37. Runx transcription factors in the development and function of the definitive hematopoietic system.
de Bruijn M; Dzierzak E
Blood; 2017 Apr; 129(15):2061-2069. PubMed ID: 28179276
[TBL] [Abstract][Full Text] [Related]
38. Normal and transforming functions of RUNX1: a perspective.
Mikhail FM; Sinha KK; Saunthararajah Y; Nucifora G
J Cell Physiol; 2006 Jun; 207(3):582-93. PubMed ID: 16250015
[TBL] [Abstract][Full Text] [Related]
39. Alternative RUNX1 Promoter Regulation by Wnt/β-Catenin Signaling in Leukemia Cells and Human Hematopoietic Progenitors.
Medina MA; Ugarte GD; Vargas MF; Avila ME; Necuñir D; Elorza AA; Gutiérrez SE; De Ferrari GV
J Cell Physiol; 2016 Jul; 231(7):1460-7. PubMed ID: 26580584
[TBL] [Abstract][Full Text] [Related]
40. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
